Explore every episode of the podcast Antibodies!

Recorded live at Antibody Engineering & Therapeutics in San Diego, Episode 3 of Antibodies! brings together leading voices from across the antibody discovery and development community for a series of conversations on some of the field’s most important challenges and opportunities.

Hosted by Jonathan Davis, PhD, Founder of Creative Antibodies, this special conference edition features discussions on target discovery, tumor specificity, bispecific and trispecific antibodies, intracellular targets, antibody developability, Fc effector functions, nanobody discovery, and the growing role of artificial intelligence in antibody research.

Featured guests include:

• Katherine Harris, PhD, Chief Development, Rondo Therapeutics; President, The Antibody Society
• Bryan Glaser, PhD, Senior Vice President of Business Development Invenra
• Bassil Dahiyat, PhD, President & Chief Executive Officer, Director, Xencor
• Jay M. Bhatt, Principal Scientist, Johnson & Johnson Innovative Medicine
• Shashi Jatiani, PhD, Director of Strategic Partnerships, SeromYx Systems
• Brandon DeKosky, PhD Associate Professor at MIT and The Ragon Institute/MGH
• Chris Szent Gyorgyi, PhD

From emerging antibody formats and next generation targeting strategies to AI enabled discovery and developability assessment, this episode offers a snapshot of the ideas shaping the future of antibody therapeutics.

We’re excited to share episode 2 of the Antibodies! podcast, recorded live at the Antibody Engineering & Therapeutics conference in San Diego.

Host ⁠Dr. Jonathan Davis⁠ PhD (Founder, Creative Antibodies) sits down with ⁠John Desjarlais⁠ PhD, Chief Scientific Officer at Xencor, to discuss learnings from two decades of antibody engineering: Fc platforms, T-cell engagers in solid tumors, and bispecifics in autoimmune disease.

In this conversation, they discuss:

• How a classical trombonist ended up engineering some of the most widely used Fc platforms in antibody therapeutics
• The KLH study that proved obexelimab could shut down B cells. Data so meaningful, John still keeps the plot on his office wall
• Why target selectivity matters more than immune environment for T-cell engagers in solid tumors
• The autoimmune gold rush: using T-cell engaging bispecifics to reset the immune system, inspired by Georg Schett’s CAR-T breakthrough
• Trispecifics, AND-gate targeting, and where bispecifics can go beyond oncology

Be sure to listen all the way to the end for a surprise treat - an improvised harmonica blues duet between Jonathan and John!

If you missed our previous episodes, you can find them here: ⁠https://tabs-antibodiespodcast.podbean.com/⁠

Antibodies! Ep. 1: The Antibody Frontier with Dr. Janine Schuurman

For our debut episode, host ⁠Dr. Jonathan Davis⁠ (Founder, Creative Antibodies) sits down with ⁠Dr. Janine Schuurman⁠ (Board member and current President of The Antibody Society & Founder, Lust for Life Science B.V., formerly SVP Antibody Research & Technology of Genmab) to discuss collaboration, curiosity, and the future of antibody therapeutics.

In this conversation, they reflect on their professional journeys and discuss:

• The mission of The Antibody Society.
• The power of community and collaboration.
• How unexpected results can lead to meaningful discoveries.
• The joy and importance of creativity, curiosity, and experimentation.
• How camaraderie sustains the antibody scientific community.

We sincerely hope you will enjoy this episode and stay with us for more conversations to come!

If you missed our previous episodes, you can find them here: ⁠https://tabs-antibodiespodcast.podbean.com/⁠